Ventricle Health provides a value-based home care model for heart failure patients. The company offers a physician-led network of cardiologists, nurses, health coaches, and pharmacists focused on optimizing heart health.

Ventricle Health

Ventricle Health exists to enable unprecedented access to high quality cardiac care including 1) expert cardiologists, 2) state of the art health monitoring devices and 3) clinically proven medicines at doses optimized for you - all from the comfort of your home.

Over 3 million patients at over 28 major medical centers in the US. 

Only 1 in 9 patients who had a guideline indication for an SGLT2i - a class of medicine that has been shown to reduce CV death, reduce the development of new onset HF, prevent HF readmissions, slow progression of renal failure and improve quality of life - actually received the therapy. 

It is time to utilize systems of care that are uniquely focused on 1) identifying these deficiencies AND 2) prescribing GDMT agents for patients that qualify. 

Ventricle Health can help overcome limitations with clinic access, time, inertia and cost to get patients on the meds they deserve. Let us help you help your patients and providers. 

#VentricleHealth #GDMT #HFEquity 

Anita Kelkar MD, MPH Greg Egnaczyk Sean O'Donnell Jason Kemmer

The heart is an amazing machine. 

It beats 100,000 times per day. 35 million times in a year and 2.5 billion times in a lifetime and we never give it a second thought unless something goes wrong. 

At Ventricle, we never take this amazing pump for granted. We feel strongly that everyone with heart failure - or other heart issues - deserves rapid assessment and the best therapies possible no matter where they live or what local resources are available  

#HFequity #VentricleHealth

Anita Kelkar MD, MPH Greg Egnaczyk Sean O'Donnell Rebecca Steele, MSN, RN, CNL Jason Kemmer Shandy Guharoy Science

The ACO Reach program was born out of the idea that if we want to improve patient outcomes, we have to work smarter, not harder. Yet, even within the ACO Reach population, heart failure is still woefully undertreated, and the effect on patient outcomes and cost of care has been drastic. The difference between a patient being treated for heart failure* and a patient left unseen is a 50% reduction in mortality and thousands of dollars per month. ACOs with higher than average readmission rates see the cost-gap widen to $20,000 per patient over just the first three months after their HF diagnosis. For the 20 worst offenders, the cost grows further, sitting between $30,000-$110,000; for ACOs of any size, this inaction is costly and lethal.  

The science is out: we know GDMT works, we know it saves money, and most importantly we know it saves lives. Yet still, undertreatment is endemic to our system. Across the entire ACO reach program, we’ve found there is a staggering $650,000,000 difference between the treated and untreated in their first 3 months of care, post-HF diagnosis.
The costs are preventable, the savings accessible - lying there on the sidewalk for anyone to pick up. Join us at Ventricle Health to add your ACO to the growing list of systems and payers who know it's time to stoop down and pick up the bill.  

If you wish to see how your specific ACO Reach compares please reach out to evan@ventriclehealth.com for a targeted cost-savings analysis.   

*Treated is defined as seeing a cardiologist within 30 days and being prescribed just one GDMT drug within 60 days

#HeartFailure #GDMT #ACO #HeartDisease #ValueBasedCare

More good news for patients with HFpEF! 

Finerenone (Kerendia) - a nonsteroidal MRA that already has great CV and renal data in patients with DM2 - meets its endpoint for a significant reduction in the combined endpoint for mortality, HF hospitalizations and acute care visits for worsening HF in patients with HFpEF. Excited to see full data soon!

GDMT just keeps getting better. Now it’s time to put the science into practice. 

#finerenone #hfpef #cardiorenal #gdmt #VentricleHealth 

Anita Kelkar MD, MPH Greg Egnaczyk Sean O'Donnell Jason Kemmer Rebecca Steele, MSN, RN, CNL

This! 👇

Patients with HF have similar mortality rates to patients with many types of cancer. And like for cancer, we have combination agents which result in marked improvements in symptoms and mortality (with a lot less side effects than chemotherapy). 

Why don’t we have the same urgency to fight HF like we fight cancer?? 

Four meds in under four months. (If not less!). Let us help your patients get there with our virtual HF titration program - optimal therapy = optimal outcomes. Everyone deserves this. 

#fightHF #GDMTworks #HFequity #VentricleHealth

Anita Kelkar MD, MPH Greg Egnaczyk Sean O'Donnell Jason Kemmer Rebecca Steele, MSN, RN, CNL

The treatment of HFpEF just got more interesting! 

Topline results from the SUMMIT trial released today showed that obese patients with HFpEF treated with tirzepatide (Mounjaro) - a GLP-1RA - lost 15.7% of their body weight  compared to 2.2% for patients in the usual care group. Patients treated with tirzepatide also had fewer HF events and greater improvements in symptoms and quality of life scores versus those treated with placebo. 

Patients in the tirzepatide arm were also more likely to require less diuretics than those in the control arm. 

Great to see more meaningful therapeutic options for our patients with HFpEF!

Hopefully approvals and indications will expand to make these agents easier to get for all of our HF patients who meet criteria. 

#HFpEF #expandingoptions #SUMMIT #VentricleHealth 

Anita Kelkar MD, MPH Greg Egnaczyk Sean O'Donnell Rebecca Steele, MSN, RN, CNL Jason Kemmer Eli Lilly and Company

Why are we diagnosing so much HF in the ER??

More that 1 million new cases of HF are diagnosed each year in the US. Early recognition of HF can lead to more rapid initiation of GDMT and save lives. 

In Circulation:HF, researchers at Stanford analyzed data from nearly 1,000,000 HF patients who were newly diagnosed with HF in an Optum database spanning 2003-2019. 

Of the 959,438 patients diagnosed with new HF in the database, 38% (!) of these were diagnosed in acute care settings (predominantly the ER). Nearly half (46%) of the cases had potential HF symptoms documented in their chart over the previous 6 months. 

Women and Black patients were more likely than men and White patients to be diagnosed in an acute setting versus as an outpatient. 

With our latest HF trials showing a statistically significant benefit in outcomes within just 12 days of medication initiation (EMPEROR-Reduced), we need to find ways to identify and treat HF earlier particularly in patients with early symptomatology. 

Biomarkers, screening home echos and newer low EF detection devices are all tools we now have in our arsenal to make this possible.

Lack of cardiology clinic access and strained resources can be overcome with digital/virtual HF partnerships. 

Let’s get this done…together. 

https://lnkd.in/gPmDCJvm

#earlydiagnosis #HFequity #VentricleHealth

Alexander Sandhu Anita Kelkar MD, MPH Greg Egnaczyk Sean O'Donnell Rebecca Steele, MSN, RN, CNL Jason Kemmer Erik Abel, PharmD, MBA Suneil Aggarwal Ventricle Health

Congratulations to the Texas Heart team and Bivacor.  Very exciting times ahead - creating new options for complex patients with advanced heart failure

Insightful conversation featuring Ventricle Health VP of Product Omar Mousa!

👏👏👏👏

Rebecca Steele, MSN, RN, CNL Sean O'Donnell Jason Kemmer Dan Bensimhon Alicia Hernandez (Smith) Medha Tandon Emir Ibrahimbegovic

Great Ventricle Health clinician meeting and #HFreview on heart failure phenotypes and overcoming clinical inertia with one of our Medical Directors and Advanced Heart Failure Cardiologist Greg Egnaczyk MD. ❤️ 

🔑  Key Takeway: "Listen to your patient when you are titrating their medications."

#Evidencebasedcare
#Heartfailure
#PurposebuiltHFclinics
#HFequity
#GDMTworks

Dan Bensimhon Anita Kelkar MD, MPH Wally Omar Sourin Banerji Frank Amico Sarah Albrecht Tara Beaird, RN, CHFN Nissa Felton BSN, RN, PCCN, CHFN Lowell Safren, M.D.Emily Friesen

VENT

COM:VENTRICLEHEALTH

Ventricle Health

locale

market

industry

website

linkedin

investor of

Metrics